European drug regulators have expanded the indication for Bayer’s blood thinner Xarelto allowing more types of patients to receive the drug. The National Institute for Health and Care Excellence (NICE) issued a final draft guidance allowing anticoagulant Xarelto to be used in combination with the antiplatelet drug clopidogrel and aspirin, or with aspirin alone, to prevent blood clots in patients who have had a heart attack. Xarelto, which contains the active ingredient rivaroxaban, is already approved to treat and prevent strokes in some heart patients and in patients with deep vein thrombosis or pulmonary embolism, and to prevent blood clots in patients ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.